Olanex Plus 5 Tablet is a combination pharmaceutical formulation containing Fluoxetine 20 mg and Olanzapine 5 mg, indicated for the management of major depressive disorder with psychotic features, treatment-resistant depression, and certain bipolar disorders. Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), acts by increasing serotonin levels in the brain, thereby improving mood and alleviating depressive symptoms. Olanzapine, an atypical antipsychotic, modulates various neurotransmitter receptors, including dopamine and serotonin receptors, contributing to its antipsychotic and mood-stabilizing effects. The synergistic action of these two agents provides enhanced efficacy in patients who do not respond adequately to monotherapy. Olanex Plus 5 is typically prescribed under medical supervision, with dosing individualized based on clinical response and tolerability. Common adverse effects may include weight gain, sedation, dry mouth, gastrointestinal disturbances, and extrapyramidal symptoms; therefore, monitoring for metabolic changes and neurological status is recommended during therapy. Caution is advised in patients with a history of cardiovascular disease, diabetes, or seizure disorders. This combination should not be abruptly discontinued to avoid withdrawal symptoms. Olanex Plus 5 Tablet should be used as part of a comprehensive treatment plan including psychotherapy and lifestyle modifications to optimize patient outcomes.